24 Apr 2015
As on that 10 new molecular entity is approved by USFDA.
|FDA-approved use on approval date
|To treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders
|To treat pediatric patients with high-risk neuroblastoma
|To treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infections
|To treat adults with complicated intra-abdominal infections (cIAI), in combination with metronidazole, and complicated urinary tract infections (cUTI), including kidney infections (pyelonephritis), who have limited or no alternative treatment options.
|To treat patients with multiple myeloma
|To treat patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite receiving radioactive iodine therapy (radioactive iodine refractory disease).
|To treat advanced (metastatic) breast cancer
|To control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidism
|To treat adults with moderate-to-severe plaque psoriasis
|To reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem